Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 240 mg - tablet, film coated - excipient ingredients: sodium alginate; powdered cellulose; purified water; magnesium stearate; hypromellose; purified talc; titanium dioxide; povidone; macrogol 400; macrogol 6000; quinoline yellow; indigo carmine; glycol/butylene glycol montanate - isoptin sr (verapamil hydrochloride) is indicated for the management of essential hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 240 mg - tablet, modified release - excipient ingredients: sodium alginate; powdered cellulose; purified water; magnesium stearate; hypromellose; purified talc; titanium dioxide; povidone; glycol/butylene glycol montanate; macrogol 400; macrogol 6000; quinoline yellow; indigo carmine - cordilox sr (verapamil hydrochloride) is indicated for the management of hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hypromellose; sodium lauryl sulfate; macrogol 6000; purified talc; titanium dioxide - anpec is indicated for:,-hypertension,-angina of effort,-angina at rest,-vasospastic angina (including prinzmetal?s variant angina),-tachyarrhythmias including paroxysmal supra-ventricular tachycardia,-atrial fibrillation with rapid ventricular response,-atrial flutter with rapid ventricular response

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hypromellose; sodium lauryl sulfate; macrogol 6000; purified talc; titanium dioxide - anpec is indicated for:,-hypertension,-angina of effort,-angina at rest,-vasospastic angina (including prinzmetal?s variant angina),-tachyarrhythmias including paroxysmal supra-ventricular tachycardia,-atrial fibrillation with rapid ventricular response,-atrial flutter with rapid ventricular response

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - phenobarbital - chewable tablet - 60 mg/tablet - phenobarbital - dogs - neurological preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - leflunomide generichealth is indicated for the treatment of: - active rheumatoid arthritis; - active psoriatic arthritis. leflunomide generichealth is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.,the combined use of leflunomide generichealth with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - leflunomide generichealth is indicated for the treatment of: - active rheumatoid arthritis; - active psoriatic arthritis. leflunomide generichealth is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.,the combined use of leflunomide generichealth with other disease modifying anti-rheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).